ReviewExpert review of molecular diagnostics2017
Care delivery considerations for widespread and equitable implementation of inherited cancer predisposition testing.
Review in Expert review of molecular diagnostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Parents' understanding of genome and exome sequencing for pediatric health conditions: a systematic review.European journal of human genetics : EJHG · 2022Pooled it
- Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017Trial
- Awareness, Attitudes, and Expectations of Indian Cancer Patients and Their Caregivers on Hereditary Cancers and Genetic Testing at a Tertiary Cancer Centre in India.Journal of genetic counseling · 2026Article
- Development and feasibility testing of a conversational chatbot supporting genetic education and testing for hereditary cancer.Journal of community genetics · 2026Article
- Cancer burden among adults aged 65 years and older in Asia, 1990-2023: a systematic analysis of the Global Burden of Disease Study 2023.npj aging · 2026Article
- Expanding access to cancer genetic care for cancer survivors: Rationale and design for a randomized controlled trial of a chatbot-based genetic education and testing.Contemporary clinical trials · 2026Article
- Investigation of interest in and timing preference for cancer predisposition testing and expanded carrier screening among women of reproductive age.PEC innovation · 2023Article
- Advancing health equity: A qualitative study assessing barriers and facilitators of implementing hereditary breast and ovarian cancer risk screening tools in community-based organizations.Journal of genetic counseling · 2023Article
- Genetic counselors' experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes.Journal of genetic counseling · 2022Article
- Interventions to improve delivery of cancer genetics services in the United States: A scoping review.Genetics in medicine : official journal of the American College of Medical Genetics · 2022Article
- Racial and ethnic disparities in diagnostic efficacy of comprehensive genetic testing for sensorineural hearing loss.Human genetics · 2022Article
- Adaptation and early implementation of the PREdiction model for gene mutations (PREMMFamilial cancer · 2022Article
- An overview of genetic services delivery for hereditary breast cancer.Breast cancer research and treatment · 2022Review
- Understanding cancer genetic risk assessment motivations in a remote tailored risk communication and navigation intervention randomized controlled trial.Health psychology and behavioral medicine · 2022Article
- Article
- Creating accessible Spanish language materials for Clinical Sequencing Evidence-Generating Research consortium genomic projects: challenges and lessons learned.Personalized medicine · 2021Article
- Development and early implementation of an Accessible, Relational, Inclusive and Actionable approach to genetic counseling: The ARIA model.Patient education and counseling · 2021Article
- Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!Oncology reviews · 2021Article
- Update on multi-gene panel testing and communication of genetic test results.The breast journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionDNA sequencing advances through next-generation sequencing (NGS) and several practice changing events, have led to shifting paradigms for inherited cancer predisposition testing. These changes necessitated a means by which to maximize health benefits without unnecessarily inflating healthcare costs and exacerbating health disparities. Areas covered: NGS-based tests encompass multi-gene panel tests, whole exome sequencing, and whole genome sequencing, all of which test for multiple genes simultaneously, compared to prior sequencing practices through which testing was performed sequentially for one or two genes. Taking an ecological approach, this article synthesizes the current literature to consider the broad impact of these advances from the individual patient-, interpersonal-, organizational-, community- and policy-levels. Furthermore, the authors describe how multi-level factors that impact genetic testing and follow-up care reveal great potential to widen existing health disparities if these issues are not addressed. Expert commentary: As we consider ways to maximize patient benefit from testing in a cost effective manner, it is important to consider perspectives from multiple levels. This information is needed to guide the development of interventions such that the promise of genomic testing may be realized by all populations, regardless of race, ethnicity and ability to pay.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.